deltatrials
Unknown PHASE2 NCT00466102

Efficacy of RAD001 in Breast Cancer Patients With Bone Metastases

RADAR: A Randomized Discontinuation Phase II Study to Determine the Efficacy of RAD001 in Breast Cancer Patients With Bone Metastases

Sponsor: GBG Forschungs GmbH

Conditions Breast Cancer
Interventions Placebo RAD001
Updated 6 times since 2017 Last updated: Aug 29, 2012 Started: Dec 31, 2006 Primary completion: Dec 31, 2010 Completion: Dec 31, 2012

A PHASE2 clinical study on Breast Cancer, this trial is ongoing. The trial is conducted by GBG Forschungs GmbH and has accumulated 6 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

6 versions recorded

  1. Apr 2025 — Present [monthly]

    Unknown PHASE2

  2. Sep 2024 — Apr 2025 [monthly]

    Unknown PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  4. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE2

    First recorded

Dec 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GBG Forschungs GmbH
  • Novartis
Data source: GBG Forschungs GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Kiel, Germany